Abstract:Amyotrophic lateral sclerosis (ALS) is an intractable disease that causes respiratory failure leading to mortality. The main locus of ALS is motor neurons. The success of antisense oligonucleotide (ASO) therapy in spinal muscular atrophy (SMA), a motor neuron disease, has triggered a paradigm shift in developing ALS therapies. The causative genes of ALS and disease-modifying genes, including those of sporadic ALS, have been identified one after another. Thus, the freedom of target choice for gene therapy has expanded by ASO strategy, leading to new avenues for therapeutic development. Tofersen for superoxide dismutase 1 (SOD1) was a pioneer in developing ASO for ALS. Improving protocols and devising early interventions for the disease are vital. In this review, we updated the knowledge of causative genes in ALS. We summarized the genetic mutations identified in familial ALS and their clinical features, focusing on SOD1, fused in sarcoma (FUS), and transacting response DNA-binding protein. The frequency of the C9ORF72 mutation is low in Japan, unlike in Europe and the United States, while SOD1 and FUS are more common, indicating that the target mutations for gene therapy vary by ethnicity. A genome-wide association study has revealed disease-modifying genes, which could be the novel target of gene therapy. The current status and prospects of gene therapy development were discussed, including ethical issues. Furthermore, we discussed the potential of axonal pathology as new therapeutic targets of ALS from the perspective of early intervention, including intra-axonal transcription factors, neuromuscular junction disconnection, dysregulated local translation, abnormal protein degradation, mitochondrial pathology, impaired axonal transport, aberrant cytoskeleton, and axon branching. We simultaneously discuss important pathological states of cell bodies: persistent stress granules, disrupted nucleocytoplasmic transport, and cryptic splicing. The development of gene therapy based on the elucidation of disease-modifying genes and early intervention in molecular pathology is expected to become an important therapeutic strategy in ALS.

Mutations of optineurin in amyotrophic lateral sclerosis

ALS-Associated E478G Mutation in Human OPTN (optineurin) Promotes Inflammation and Induces Neuronal Cell Death

Multiple Proteinopathies in Familial ALS Cases With Optineurin Mutations

The Diverse Role of Optineurin in Pathogenesis of Disease.

Four novel optineurin mutations in patients with sporadic amyotrophic lateral sclerosis in Mainland China

Optineurin Mutations in Patients with Sporadic Amyotrophic Lateral Sclerosis in China.

Optineurin-facilitated axonal mitochondria delivery promotes neuroprotection and axon regeneration

Differential Involvement Of Optineurin In Amyotrophic Lateral Sclerosis With Or Without Sod1 Mutations

Effects of optineurin mutants on SH-SY5Y cell survival

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions

Loss of nucleoporin Nup50 is a risk factor for amyotrophic lateral sclerosis

The E50K optineurin mutation impacts autophagy-mediated degradation of TDP-43 and leads to RGC apoptosis in vivo and in vitro

C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity

Genetics of motor neuron disorders: new insights into pathogenic mechanisms

Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy

Optineurin Immuno-Reactive Inclusions Are A Common Feature In Sporadic And Non-Sod1 Familial Amyotrophic Lateral Sclerosis

Effects of Pathogenic Mutants of the Neuroprotective RNase 5-Angiogenin in Amyotrophic Lateral Sclerosis (ALS)

Transcriptional modulation unique to vulnerable motor neurons predicts ALS across species and SOD1 mutations

Identification of a pathogenic mutation in ARPP21 in patients with amyotrophic lateral sclerosis

Novel Mutations in Malonyl-Coa-acyl Carrier Protein Transacylase Provoke Autosomal Recessive Optic Neuropathy.